If you think it’s an AFE, call us! 1-307-363-2337 (1-307-END-AFES)

Registry & Biorepository

One of the primary objectives of the AFE Foundation is to advance research of amniotic fluid embolism (AFE) to elucidate the etiology and pathophysiology of AFE. Through this understanding we hope to establish an effective treatment, mechanism for predictability, and a gold standard diagnostic test.

Together, with a team of multidisciplinary expert researchers from various universities the AFE Registry and Biorepository was established in 2012. 

Attendees at the International Amniotic-Fluid Conference

Leading AFE expert and researcher, Steven Clark, stated in his widely cited manuscript,

The greatest opportunity to advance our understanding of this condition is to support the efforts of the AFE Foundation’s AFE Patient Registry and Biorepository. [1]

The AFE Biorepository was established to allow for the collection, storage, and examination of blood and tissues from AFE patients which are needed to help transform this syndrome into a predictable, preventable, and treatable condition. Considerable focus is on the identification of mechanisms of disease and the biomarkers responsible for this syndrome.

The AFE Registry and Biorepository reside at the University of Texas Health Science Center / McGovern Medical School in Houston, Texas, and is overseen by Primary Investigator, Dr. Irene Stafford, MD. Director of Research, Sunbola Ashimi, Ph.D., and Co-Investigator, Miranda Klassen.

Learn more about our research efforts at ClinicalTrials.gov.


Blood tests taken before and during an AFE event may hold the key to unlocking the mystery of AFE.

Diagnostic Criteria

Published Abstracts and Articles

Notable Articles Mentioning AFE Foundation

[1] Clark SL. Amniotic fluid embolism. Obstet Gynecol. 2014 Feb;123(2 Pt 1):337-348.